These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23212767)

  • 1. Interim treatment selection with a flexible selection margin in clinical trials.
    Wu Y; Zhao PL
    Stat Med; 2013 Jul; 32(15):2529-43. PubMed ID: 23212767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Many-to-one comparison after sample size reestimation for trials with multiple treatment arms and treatment selection.
    Wang J
    J Biopharm Stat; 2010 Sep; 20(5):927-40. PubMed ID: 20721782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval estimation in two-stage, drop-the-losers clinical trials with flexible treatment selection.
    Neal D; Casella G; Yang MC; Wu SS
    Stat Med; 2011 Oct; 30(23):2804-14. PubMed ID: 21823142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
    Zhang Z; Chen R; Soon G; Zhang H
    Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive Dunnett tests for treatment selection.
    Koenig F; Brannath W; Bretz F; Posch M
    Stat Med; 2008 May; 27(10):1612-25. PubMed ID: 17876763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An adaptive confirmatory trial with interim treatment selection: practical experiences and unbalanced randomization.
    Heritier S; Lô SN; Morgan CC
    Stat Med; 2011 Jun; 30(13):1541-54. PubMed ID: 21432887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim.
    Posch M; Maurer W; Bretz F
    Pharm Stat; 2011; 10(2):96-104. PubMed ID: 22328314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A group-sequential design for clinical trials with treatment selection.
    Stallard N; Friede T
    Stat Med; 2008 Dec; 27(29):6209-27. PubMed ID: 18792085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim treatment selection using the normal approximation approach in clinical trials.
    Shun Z; Lan KK; Soo Y
    Stat Med; 2008 Feb; 27(4):597-618. PubMed ID: 17619239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal response-adaptive randomized designs for multi-armed survival trials.
    Sverdlov O; Tymofyeyev Y; Wong WK
    Stat Med; 2011 Oct; 30(24):2890-910. PubMed ID: 21823146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A flexible design for multiple armed screening trials.
    Sargent DJ; Goldberg RM
    Stat Med; 2001 Apr; 20(7):1051-60. PubMed ID: 11276035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of multiple testing procedures for the gold standard non-inferiority trial.
    Röhmel J; Pigeot I
    J Biopharm Stat; 2010 Sep; 20(5):911-26. PubMed ID: 20721781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Issues with statistical risks for testing methods in noninferiority trial without a placebo ARM.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(2):201-13. PubMed ID: 17365218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the efficiency of two-stage response-adaptive designs.
    Dette H; Bornkamp B; Bretz F
    Stat Med; 2013 May; 32(10):1646-60. PubMed ID: 22865374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-arm multi-stage (MAMS) randomised selection designs: impact of treatment selection rules on the operating characteristics.
    Choodari-Oskooei B; Blenkinsop A; Handley K; Pinkney T; Parmar MKB
    BMC Med Res Methodol; 2024 Jun; 24(1):124. PubMed ID: 38831421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed noninferiority margin and statistical tests in active controlled trials.
    Tsou HH; Hsiao CF; Chow SC; Yue L; Xu Y; Lee S
    J Biopharm Stat; 2007; 17(2):339-57. PubMed ID: 17365228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The advantages and disadvantages of adaptive designs for clinical trials.
    Bauer P; Brannath W
    Drug Discov Today; 2004 Apr; 9(8):351-7. PubMed ID: 15081962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Add-Arm Design for Unimodal Response Curve with Unknown Mode.
    Chang M; Wang J
    J Biopharm Stat; 2015; 25(5):1039-64. PubMed ID: 25331003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.